Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.54 HKD
Change Today -0.16 / -22.86%
Volume 580.0K
8189 On Other Exchanges
Symbol
Exchange
Hong Kong
As of 11:19 PM 07/7/15 All times are local (Market data is delayed by at least 15 minutes).

tianjin teda biomedical-h (8189) Snapshot

Open
$0.68
Previous Close
$0.70
Day High
$0.68
Day Low
$0.37
52 Week High
04/28/15 - $1.80
52 Week Low
07/8/15 - $0.37
Market Cap
870.8M
Average Volume 10 Days
427.5K
EPS TTM
$0.01
Shares Outstanding
897.5M
EX-Date
--
P/E TM
37.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for TIANJIN TEDA BIOMEDICAL-H (8189)

Related News

No related news articles were found.

tianjin teda biomedical-h (8189) Related Businessweek News

No Related Businessweek News Found

tianjin teda biomedical-h (8189) Details

Tianjin TEDA Biomedical Engineering Company Limited, together with its subsidiaries, is engaged in the research, development, manufacture, and sale of biological compound fertilizer products and health care products in the People’s Republic of China. It operates in two segments, Compound Fertilizers Products and Health Care Products. The company markets its biological compound fertilizer products under the Fulilong brand, which are used for the balanced growth of grains, fruits, and vegetables. It also offers a series of health care products under the Alpha brand comprising diabetic health care products and related products with the function of regulating the blood sugar level; and various sugar-free products, including beverages, low glucose cookies, cereals, calcium-rich milk powder, and mooncakes. The company was founded in 2000 and is headquartered in Tianjin, the People's Republic of China.

500 Employees
Last Reported Date: 03/27/15
Founded in 2000

tianjin teda biomedical-h (8189) Top Compensated Officers

Executive Chairman, Chief Executive Officer, ...
Total Annual Compensation: CNY616.2K
Vice Chairman
Total Annual Compensation: CNY589.7K
Executive Director
Total Annual Compensation: --
Company Secretary
Total Annual Compensation: CNY150.0K
Compensation as of Fiscal Year 2014.

tianjin teda biomedical-h (8189) Key Developments

Tianjin TEDA Biomedical Engineering Company Limited Announces Board Changes

Tianjin TEDA Biomedical Engineering Company Limited announced that the Board has accepted the resignations of Mr. Xie Guangbei, a non-executive Director and Mr. Zhao Kuiying, an Independent Supervisor with effect from 30 June 2015. Mr. Chen Yingzhong, an executive Director will be redesignated as a non-executive Director of the Company with effect from the date of approval by the Shareholders and expiring on 31 December 2016. The Board proposed to appoint Ms. Sun Li as an executive Director and Mr. Liang Weitao as an Independent Supervisor for a term commencing on the date of approval by the Shareholders and expiring on 31 December 2016. Mr. Xie Guangbei tendered a written notice to resign as a non-executive Director and a member of the Remuneration Committee of the Company due to his busy schedule and increasing commitments in other business which make him no longer possible to spend sufficient time on the business of the Company. Mr. Zhao Kuiyin also tendered a written notice to resign as an Independent Supervisor of the Company as his current working location in Tang Shan is too distant from the Company which renders him not possible to fulfill his duty as an Independent supervisor of the Company.

Tianjin TEDA Biomedical Engineering Company Limited Announces Consolidated Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Tianjin TEDA Biomedical Engineering Company Limited announced consolidated unaudited earnings results for the first quarter ended March 31, 2015. For the three months ended 31 March 2015, the Group achieved a consolidated turnover of RMB 130,181,487, representing a decrease of 4.9% as compared to the same period of last year (31 March 2014: RMB 136,906,003). In particular, the Group recorded a sales turnover of RMB 108,672,424 for compound fertilizer products, representing a decrease of 7.7% as compared to the same period of last year (31 March 2014: RMB 117,722,388); the Group recorded a sales turnover of RMB 21,509,063 for health care products, representing an increase of 12.1% as compared to the same period of last year (31 March 2014: RMB 19,183,615). For the quarter, the company reported loss before tax was RMB 77,194 compared with profit before tax of RMB 4,148,387 for the same period a year ago. Profit attributable to owners of the parent company was RMB 2,651,479 or 0.187 cents per basic share compared with RMB 4,157,162 or 0.293 cents per basic share for the same period a year ago.

Tianjin TEDA Biomedical Engineering Company Limited Appoints Guan Tong as the Chairman of the Audit Committee

Tianjin TEDA Biomedical Engineering Company Limited announced that Mr. Guan Tong has been appointed as the chairman of the Audit committee due to his professional qualifications in accounting and auditing experience.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
8189:HK $0.54 HKD -0.16

8189 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 8189.
View Industry Companies
 

Industry Analysis

8189

Industry Average

Valuation 8189 Industry Range
Price/Earnings 48.8x
Price/Sales 1.5x
Price/Book 4.0x
Price/Cash Flow 54.8x
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TIANJIN TEDA BIOMEDICAL-H, please visit www.bioteda.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.